CAC
SRNE

Cowen and Company’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cowen and Company’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-129,200
Closed -$1.44M – 552
2020
Q3 		$1.44M Buy
+129,200
New +$1.18M 0.24% 69

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen and Company's SRNE Position: Q4 2020 in Review

Cowen and Company sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 129,200 shares — an estimated $1.44M sold.

Cowen and Company first reported a position in SRNE in Q3 2020 and held it in 1 quarter. The position peaked at $1.44M in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Cowen and Company reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Cowen and Company sold 129,200 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $1.44M.
  • Cowen and Company first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Cowen and Company's Sorrento Therapeutics, Inc. position peaked at $1.44M in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.